Back

COVID-19 and heart medications: What's the connection?

Saleknezhad, N.; Khosravi, B.; Anushiravani, A.; Eslahi, M.; Radmard, A. R.; Sirusbakht, A.; Pourabbas, S. M.; Abdollahi, M.; Kasaeian, A.; Sorouri, M.; Sima, A. R.

2020-08-26 cardiovascular medicine
10.1101/2020.08.24.20174367 medRxiv
Show abstract

AimTo determine association between clinical outcome of COVID-19 and prior usage of cardiovascular and metabolic drugs, including, Aspirin, ACEIs, ARBs, Clopidogrel, metformin, and Statins. MethodsStatistical examination of the demographic, clinical, laboratory and imaging features of 353 patients with SARS-CoV-2 disease admitted from February to April 2020. ResultMinor discrepancies were observed in the clinical presentations, radiologic involvement and laboratory results across groups of patients under treatment with specific drugs. Aspirin-users had better clinical outcome with lower need of ventilation support, whereas, metformin- users had increased chance of intubation and of mortality. ConclusionAlthough not being conclusive, our findings suggest the possibility of the effect of previous drug usages on the various presentations and clinical course of COVID-19 infection.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.